Gene therapy of the typical multidrug resistance phenotype of cancers: A new hope?

Seminars in Oncology

Volumn 32, Issue 6, 2005, Pages 583-590

  Labialle, Stéphane ^a   Dayan, Guila ^b   Michaud, Mickaël ^b   Barakat, Stéphane ^b   Rigal, Dominque ^c   Baggetto, Loris G ^b,d  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DNA; DOUBLE STRANDED DNA; HOMOPURINE OLIGONUCLEOTIDE; HOMOPYRIDINE OLIGONUCLEOTIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEAR FACTOR; OLIGONUCLEOTIDE; RECOMBINANT DNA; RIBOZYME; RNA; TRANSCRIPTION FACTOR; TRIPLE FORMING OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENETICS; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TRANSGENE; TREATMENT PLANNING;

EID: 28844462998     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.09.008     Document Type: Article

References (77)

1. J. Stefkova, R. Poledne, J.A. Hubacek ATP-binding cassette (ABC) transporters in human metabolism and diseases Physiol Res 53 2004 235 243
2. G.L. Scheffer, P.L. Wijngaard, M.J. Flens The drug resistance-related protein LRP is the human major vault protein Nat Med 1 1995 578 582
3. G. Rappa, R.A. Finch, A.C. Sartorelli New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models Biochem Pharmacol 58 1999 557 562
4. G. Vasanthakumar, N.K. Ahmed Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates Cancer Commun 1 1989 225 232
5. S.K. Alahari, N.M. Dean, M.H. Fisher Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides Mol Pharmacol 50 1996 808 819
6. C. Cucco, B. Calabretta In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides Cancer Res 56 1996 4332 4337
7. S. Motomura, T. Motoji, M. Takanashi Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides Blood 91 1998 3163 3171
8. H. Dassow, D. Lassner, H. Remke Modulation of P-glycoprotein-mediated multidrug resistance in a doxorubicin-resistant subline of the human lymphoblastoid cell line CCRF-CEM by phosphorothioate antisense oligonucleotides Int J Clin Pharmacol Ther 36 1998 93 96
9. P. Yaswen, M.R. Stampfer, K. Ghosh Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells Antisense Res Dev 3 1993 67 77
10. J.L. Vaerman, C. Lammineur, P. Moureau BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism Blood 86 1995 3891 3896
11. S.T. Crooke Therapeutic applications of oligonucleotides Annu Rev Pharmacol Toxicol 32 1992 329 376
12. I. Brigui, T. Djavanbakht-Samani, B. Jolles Minimally modified phosphodiester antisense oligodeoxyribonucleotide directed against the multidrug resistance gene mdr1 Biochem Pharmacol 65 2003 747 754
13. K. Kruger, P.J. Grabowski, A.J. Zaug Self-splicing RNA Autoexcision and autocyclization of the ribosomal RNA intervening sequence of tetrahymena Cell 31 1982 147 157
14. C. Guerrier-Takada, K. Gardiner, T. Marsh The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme Cell 35 1983 849 857
15. O.C. Uhlenbeck A small catalytic oligoribonucleotide Nature 328 1987 596 600
16. J.M. Buzayan, A. Hampel, G. Bruening Nucleotide sequence and newly formed phosphodiester bond of spontaneously ligated satellite tobacco ringspot virus RNA Nucleic Acids Res 14 1986 9729 9743
17. H. Kobayashi, Y. Takemura, H. Miyachi Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics Hum Cell 14 2001 172 184
18. Z. Gao, J.Z. Fields, B.M. Boman Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells Int J Cancer 82 1999 346 352
19. K. Palfner, M. Kneba, W. Hiddemann Improvement of hammerhead ribozymes cleaving mdr-1 mRNA Biol Chem Hoppe Seyler 376 1995 289 295
20. M. Kiehntopf, M.A. Brach, T. Licht Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells EMBO J 13 1994 4645 4652
21. P.S. Holm, M. Dietel, G. Krupp Similar cleavage efficiencies of an oligoribonucleotide substrate and an mdr1 mRNA segment by a hammerhead ribozyme Gene 167 1995 221 225
22. C. Morassutti, B. Scaggiante, L.E. Xodo Reduction of mdr1 gene amplification in human multidrug-resistant LoVo DX cell line is promoted by triple helix-forming oligonucleotides Antisense Nucleic Acid Drug Dev 9 1999 261 270
23. 125I-labeled triplex-forming oligonucleotides Antisense Nucleic Acid Drug Dev 10 2000 443 452
24. E. Marthinet, G. Divita, J. Bernaud Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter Gene Ther 7 2000 1224 1233
25. S. Labialle, G. Dayan, L. Gayet New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein Nucleic Acids Res 32 2004 3864 3876
26. M.T. McManus, P.A. Sharp Gene silencing in mammals by small interfering RNAs Nat Rev Genet 3 2002 737 747
27. A. Dillin The specifics of small interfering RNA specificity Proc Natl Acad Sci U S A 100 2003 6289 6291
28. T. Tuschl Expanding small RNA interference Nat Biotechnol 20 2002 446 448
29. C. Nieth, A. Priebsch, A. Stege Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi) FEBS Lett 545 2003 144 150
30. H. Wu, W.N. Hait, J.M. Yang Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells Cancer Res 63 2003 1515 1519
31. E. Yague, C.F. Higgins, S. Raguz Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1 Gene Ther 11 2004 1170 1174
32. D. Xu, H. Kang, M. Fisher Strategies for inhibition of MDR1 gene expression Mol Pharmacol 66 2004 268 275
33. J. Hua, D.G. Mutch, T.J. Herzog Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line Gynecol Oncol 98 2005 31 38
34. T. Zhang, M. Guan, H.Y. Jin Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells Gynecol Oncol 97 2005 501 507
35. V.V. Bartsevich, R.L. Juliano Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinatorial libraries Mol Pharmacol 58 2000 1 10
36. D. Xu, D. Ye, M. Fisher Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator J Pharmacol Exp Ther 302 2002 963 971
37. M. Kuznetsova, A. Fokina, M. Lukin Catalytic DNA and RNA for targeting MDR1 mRNA Nucleosides Nucleotides Nucleic Acids 22 2003 1521 1523
38. W. Niewiarowski, E. Gendaszewska, G. Rebowski Multidrug resistance-associated protein-reduction of expression in human leukaemia cells by antisense phosphorothioate olignucleotides Acta Biochim Pol 47 2000 1183 1188
39. A.E. Peaston, M. Gardaneh, A.V. Franco MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells Br J Cancer 85 2001 1564 1571
40. S. Kawabata, M. Oka, K. Shiozawa Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells Biochem Biophys Res Commun 280 2001 1216 1223
41. H. Hatanaka, Y. Abe, M. Naruke Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme Anticancer Res 21 2001 879 885
42. J. Nagata, H. Kijima, H. Hatanaka Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene Int J Oncol 21 2002 1021 1026
43. P. Kowalski, U. Stein, G.L. Scheffer Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2 Cancer Gene Ther 9 2002 579 586
44. S. Akiyama, Z.S. Chen, M. Kitazono Mechanisms for resistance to anticancer agents and the reversal of the resistance Hum Cell 12 1999 95 102
45. H. Kobayashi, T. Dorai, J.F. Holland Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme Cancer Res 54 1994 1271 1275
46. F. Shi, D. Hoekstra Effective intracellular delivery of oligonucleotides in order to make sense of antisense J Control Release 97 2004 189 209
47. C.M. Roth, S. Sundaram Engineering synthetic vectors for improved DNA delivery Insights from intracellular pathways Annu Rev Biomed Eng 6 2004 397 426
48. J.P. Desjardins, P.L. Iversen Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo J Pharmacol Exp Ther 275 1995 1608 1613
49. Datamonitor. Antisense therapy: technical aspects and commercial opportunities Reuters Business Insight 2000 187 198
50. R.S. Geary, J.M. Leeds, S.P. Henry Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides Anticancer Drug Des 12 1997 383 393
51. A. Astriab-Fisher, D.S. Sergueev, M. Fisher Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates Biochem Pharmacol 60 2000 83 90
52. F. Farzaneh, U. Trefzer, W. Sterry Gene therapy of cancer Immunol Today 19 1998 294 296
53. A.B. Deisseroth Clinical trials involving multidrug resistance transcription units in retroviral vectors Clin Cancer Res 5 1999 1607 1609
54. H. Eid, I. Bodrogi, B. Csokay Multidrug resistance of testis cancers The study of clinical relevance of P-glycoprotein expression Anticancer Res 16 1996 3447 3452
55. V. Ling Multidrug resistance Molecular mechanisms and clinical relevance Cancer Chemother Pharmacol 40 suppl 1997 S3 S8
56. S. Galimberti, R. Testi, F. Guerrini The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia J Chemother 15 2003 374 379
57. C.A. Schmitt, C.T. Rosenthal, S.W. Lowe Genetic analysis of chemoresistance in primary murine lymphomas Nat Med 6 2000 1029 1035
58. L.A. Garraway, B. Chabner MDR1 inhibition Less resistance or less relevance? Eur J Cancer 38 2002 2337 2340
59. F. Cabral Factors determining cellular mechanisms of resistance to antimitotic drugs Drug Resist Update 4 2001 3 8
60. A.H. Schinkel, J.J. Smit, O. van Tellingen Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 1994 491 502
61. C. Hesdorffer, J. Ayello, M. Ward Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation J Clin Oncol 16 1998 165 172
62. H.G. Eckert, K. Kuhlcke, A.J. Schilz Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1) Bone Marrow Transplant 25 suppl 2 2000 S114 S117
63. A. Persidis Cancer multidrug resistance Nat Biotechnol 18 2000 IT18 IT20
64. A. Persidis Cancer multidrug resistance Nat Biotechnol 17 1999 94 95
65. J.M. Brown, A.J. Giaccia The unique physiology of solid tumors Opportunities (and problems) for cancer therapy Cancer Res 58 1998 1408 1416
66. S. Kuriyama, T. Sakamoto, K. Masui Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma Int J Cancer 71 1997 470 475
67. Z. Yan, A.L. Serrano, S. Schiaffino Regulatory elements governing transcription in specialized myofiber subtypes J Biol Chem 276 2001 17361 17366
68. J.P. Latham, P.F. Searle, V. Mautner Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer Construction and testing of a tissue-specific adenovirus vector Cancer Res 60 2000 334 341
69. G.H. Swift, F. Kruse, R.J. MacDonald Differential requirements for cell-specific elastase I enhancer domains in transfected cells and transgenic mice Genes Dev 3 1989 687 696
70. D.S. Anson, T. Occhiodoro Transcriptional activity of the CD45 gene promoter in retroviral vector constructs Biochim Biophys Acta 1219 1994 81 88
71. S. Kudo, M. Fukuda Tissue-specific transcriptional regulation of human leukosialin (CD43) gene is achieved by DNA methylation J Biol Chem 270 1995 13298 13302
72. M. Brenner, W.C. Kisseberth, Y. Su GFAP promoter directs astrocyte-specific expression in transgenic mice J Neurosci 14 1994 1030 1037
73. R. Vile, N. Miller, Y. Chernajovsky A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes Gene Ther 1 1994 307 316
74. P. He, Z.Y. Tang, S.L. Ye The targeted expression of interleukin-2 in human hepatocellular carcinoma cells J Exp Clin Cancer Res 19 2000 183 187
75. K.H. Lan, F. Kanai, Y. Shiratori In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma Cancer Res 57 1997 4279 4284
76. L.G. Hudson, A.P. Ertl, G.N. Gill Structure and inducible regulation of the human c-erb B2/neu promoter J Biol Chem 265 1990 4389 4393
77. L. Chen, D. Chen, Y. Manome Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter J Clin Invest 96 1995 2775 2782